NCT00068653View on ClinicalTrials.gov

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2007

Study Completion Date

May 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

Celecoxib

Celecoxib 400mg orally two times a day, taken with meals.

DRUG

ZD1839

ZD1839 250 mg po every day, taken with or without food.

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00068653 - Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter